金沙集团1862cc(股份)有限公司-baidu百科

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. specialty division ofIntas Pharmaceuticals, Ltd.(&qu...

View Details

03-262025

Bio-Thera and Dr. Reddy’s Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

Guangzhou, China/ Hyderabad, India – March 26,2025 – Bio-Thera Solutions (688177:SH; “Bio-Thera”), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies andbiosimilars, and Dr. Reddy’s Laboratories SA, wholly-owned...
02-102025

Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), in the United States of

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies and biosimilars,today announced the companyhas reached an exclusivecommercialization and license agreement...
01-162025

Bio-Thera and World Medicine Signs an Exclusive License and Commercialisation Agreement for BAT2206, a Proposed Stelara® Biosimilar

Bio-TheraSolutions, a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars hassigned an exclusive License and Commercialisation Agreement with WorldMedicine, Türkiye'spharmaceutical export champion, ...

金沙集团1862cc(股份)有限公司-baidu百科

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

Bio-Thera and Dr. Reddy’s Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), in the United States of

Bio-Thera and World Medicine Signs an Exclusive License and Commercialisation Agreement for BAT2206, a Proposed Stelara® Biosimilar